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Abstract: Pulmonary arterial hypertension (PAH) is a progressive lung disease diagnosed 
by an increase in pulmonary arterial blood pressure that is driven by a progressive vascular 
remodelling of small pulmonary arterioles. We have previously reported that tumor 
necrosis factor apoptosis-inducing ligand (TRAIL) protein expression is increased in 
pulmonary vascular lesions and pulmonary artery smooth muscle cells (PASMC) of 
patients with idiopathic PAH. The addition of recombinant TRAIL induces the 
proliferation and migration of PASMCs in vitro. TRAIL is required for hypoxia-induced 
pulmonary hypertension in mice, and blockade of TRAIL prevents and reduces disease 
development in other rodent models of PAH. Due to the availability of knockout and 
transgenic mice, murine models of disease are key to further advances in understanding the 
complex and heterogeneous pathogenesis of PAH. However, murine models vary in their 
disease severity, and are often criticized for lacking the proliferative pulmonary vascular 
lesions characteristic of PAH. The murine Sugen-hypoxic (SuHx) mouse model has 
recently been reported to have a more severe PAH phenotype consisting advanced 
pulmonary vascular remodelling. We therefore aimed to determine whether TRAIL was 
also required for the development of PAH in this model. C57BL/6 and TRAIL−/− mice 
were exposed to normoxia, Sugen5416 alone, hypoxia or both Sugen5416 and hypoxia 
(SuHx). We report here that SuHx treated C57BL/6 mice developed more severe PAH than 
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hypoxia alone, and that TRAIL−/− mice were protected from disease development. These 
data further emphasise the importance of this pathway and support the use of the SuHx 
mouse model for investigating the importance of potential mediators in PAH pathogenesis. 
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1. Introduction 
Pulmonary hypertension (PH) is a broad group of diseases defined by a mean pulmonary artery 
pressure (mPAP) of greater than or equal to 25 mmHg at right heart catheterisation [1]. Pulmonary 
arterial hypertension (PAH) is a sub-classification of PH and a progressive and degenerative disease 
driven by progressive arterial remodelling within the pulmonary circulation [2]. PAH is a rare disease, 
with an incidence of 1–3.3 per million per year (idiopathic PAH) and a prevalence of 15–52 per 
million [1] but has severe morbidity, a prognosis worse than many cancers and is ultimately fatal 
(without lung transplantation). Although PAH is a disease of the lungs, it is the impact on the right 
ventricle which ultimately defines a patients survival. The increased pulmonary vascular resistance 
results in a pressure afterload that drives a process of adaptive, then maladaptive right ventricular 
hypertrophy, dilation and stiffening. This leads to impaired stroke volume, inadequate organ perfusion 
and eventual right heart failure [3]. Current treatments for PAH are effective in alleviating 
vasoconstrictive symptoms, however they do not address the underlying pulmonary vascular or right 
ventricular remodelling and have only modest impact on patient survival.  
The increase in pulmonary pressure observed in PAH is largely due to underlying remodelling of 
small-to-medium sized pulmonary arterioles. The underlying mechanisms that lead to the pulmonary 
vascular remodelling are incredibly complex [4,5]. Although the exact trigger for pulmonary arteriole 
remodelling is currently unknown, pulmonary arterial endothelial cell (PA-EC) dysfunction and 
apoptosis is believed to be an early insult. PA-EC apoptosis causes the obliteration of distal pulmonary 
arterioles and exposes the underlying pulmonary arterial smooth muscle cells (PA-SMCs) to a whole 
host of mitogenic and vasoconstrictive factors, which then drive the vascular remodelling [4,5]. A 
population of dysfunctional, hyper-proliferative PA-ECs also proliferate to form plexiform lesions, a 
hallmark of severe PAH [6]. Growth factors, such as PDGF [7,8] and cytokines such as IL-1 and  
IL-6 [9–13] have also been implicated in the pathogenesis of PAH. More recently, we have described 
TRAIL as a critical downstream mediator of disease [14]. 
TRAIL (TNF-related apoptosis inducing ligand, Apo2L) is a type two membrane protein that is 
predominantly expressed in the lung, spleen and prostate [15]. TRAIL binds to four membrane 
receptors: TRAIL R1 (death receptor 4, DR4) [16], TRAIL R2 (death receptor 5, DR5) [16,17], 
TRAIL R3 (decoy receptor 1, DcR1) [16,18] and TRAIL R4 (decoy receptor 2, DR2) [19,20]. There is 
also a fifth, soluble decoy receptor, osteoprotegerin (OPG) [21], a putative biomarker for IPAH [22]. 
TRAIL induces the proliferation and migration of both rat and human aortic SMCs, and human 
pulmonary artery smooth muscle cells predominately via TRAIL-R3 [14,23]. TRAIL protein 
expression has also been observed in concentric and plexiform pulmonary vascular lesions in patients 
with IPAH [24] and in animal models of disease [11,14]. In rodent models anti-TRAIL antibody 
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prevents disease development [14]. Furthermore, in therapeutic studies, where antibody treatment was 
performed in models with established disease, an anti-TRAIL antibody successfully reduced 
pulmonary vascular remodelling and increased survival [14]. 
Due to the availability of knockout and transgenic mice, murine models of disease are key to further 
advances in understanding the complex and heterogeneous pathogenesis of PAH. The most common 
murine model is the chronic hypoxic mouse model [25], however the mouse is a poor responder to 
hypoxia in comparison to other species, and therefore often criticized as a poor model of PAH [26]. 
More recently, an adaptation of the rat Sugen-hypoxic (SuHx) model, first developed by 
Taraseviciene-Stewart and colleagues [27], to mice has been shown to display a more severe disease 
phenotype, with higher right heart pressure and more severe pulmonary vascular remodelling than 
hypoxia alone [28]. We therefore aimed to both establish the murine model of SuHx and hypothesised 
that TRAIL−/− mice would be protected from developing PAH in this model. We found that while 
C57BL/6 mice developed the hallmarks of PAH including remodelling of the small pulmonary 
arterioles, increased right heart pressure and right ventricular hypertrophy, TRAIL−/− mice showed no 
significant signs of PAH. 
2. Experimental Section  
2.1. Animals  
All mice were on a C57BL/6 background. TRAIL−/− mice were originally developed by 
Amgen/Immunex (Thousand Oaks, CA, USA.) as previously described [29,30] and obtained by 
material transfer agreement from Amgen Inc. (MTA # 200908042). For all procedures male C57BL/6 
and TRAIL−/− mice aged 12–13 weeks of age were used (6–8 per group). For the chronic hypoxic 
mouse model, mice were placed in hypoxic chambers (10% v/v Oxygen) for 3 weeks to induce 
pulmonary hypertension. For the Sugen-hypoxic model, C57BL/6 and TRAIL−/− were exposed to 
hypoxia (10% v/v O2) for 3 weeks with weekly injections of 20 mg/kg Sugen5416 (Tocris) during 
exposure to hypoxia as previously described [28]. All animal experiments were approved by the University 
of Sheffield Project Review Committee and conformed to UK Home Office ethical guidelines. 
2.2. Echocardiography 
Echocardiography was performed using the Vevo 770 system (VisualSonics, Toronto, Canada) 
using the RMV707B scan head. Rodents were placed on a heated platform and covered to minimise 
heat loss. Rectal temperature, heart rate and respiratory rate were recorded continuously throughout the 
study. Echocardiography was performed and analysed as previously described [11,14]. 
2.3. Cardiac Catheterisation 
Following echocardiography, left and right ventricular catheterisation was performed using a closed 
chest method via the right internal carotid artery and right external jugular vein under isoflurane 
induced anaesthesia, as previously described [11,14]. Data were collected using either a Millar 
pressure-volume PVR-1045 1F catheter (mouse LV) or PVR-1030 (mouse RV) (Millar Instruments 
Inc., Texas, USA) coupled to a Millar MPVS 300 and a PowerLab 8/30 data acquisition system (AD 
Diseases 2014, 2 263 
 
Instruments, Oxfordshire, UK) and recorded using Chart v7 software (AD Instruments). Pressure 
volume analysis was performed (PVAN, Millar) and an estimated pulmonary vascular resistance index 
(ePVRi) was calculated as previously described [14].  
2.4. Right Ventricular Hypertrophy 
Right ventricular hypertrophy (RVH) was measured by calculating the ratio of the right ventricular 
free wall over left ventricle plus septum [14]. 
2.5 Immunohistochemistry 
Immediately after harvest, the left lung was perfusion fixed via the trachea with 10% (v/v) formal 
buffered saline by inflation to 20 cm of H2O. The lungs were then processed into paraffin blocks for 
sectioning. Paraffin embedded sections (5 µm) of lung were histologically stained for Alcian Blue 
Elastin van Gieson (ABEVG) and immunohistochemically stained for α-smooth muscle actin (α-SMA, 
M0851, Dako, Cambridgeshire, UK) to visualize smooth muscle cells, TRAIL (TRAIL (ab2435; 
Abcam) was also used to localize protein expression to pulmonary vascular lesions and anti-human 
PCNA antibody to assess proliferation (M0879; Dako). A secondary biotinylated anti-mouse antibody 
(1:200) was added before an Avidin Biotin enzyme Complex (Vectastain kit;Vector Laboratories). All 
protocols used 3,3 diaminobenzidine as the substrate for color in the peroxidase reaction and 
counterstained with hematoxylin as previously described [14]. 
2.6. Quantification of Pulmonary Vascular Remodelling 
Pulmonary vascular remodelling was quantified by assessing the degree of muscularization and the 
percentage of affected pulmonary arteries and arterioles in 3 groups based on vessel size; small 
pulmonary arterioles with a diameter less than 50 µm, medium pulmonary arteries with a range in 
diameter from 51 to 100 µm, and large pulmonary arteries with a diameter greater than 100 µm and 
standard immunohistochemical techniques were applied as previously described [11,14]. 
2.7. Western Immunoblotting 
30 µg of each sample was loaded on a 4%–12% Bis-Tris NuPage gel and run under reducing 
conditions in MES running buffer (Invitrogen), before transfer to a nitrocellulose membrane 
(Invitrogen). Trans- fer was confirmed with Ponceau S (Sigma-Aldrich) staining and the membrane 
was then blocked for 1 h in Odyssey® blocking buffer (LI-COR Biosciences) at room temperature. 
The blots were incubated with either GAPDH (1:1,000, CST) or anti–beta-Actin mouse monoclonal 
antibody (1:1,000, Abcam) for 1 h at room temperature and anti-TRAIL mouse monoclonal antibody 
(1:50, Leica Biosystems) or anti-BMPR2 mouse monoclonal antibody (1:250), overnight at 4 °C. For 
detection, membranes were incubated with fluorescently labeled anti-rabbit (IRDye 800CW; LI-COR 
Biosciences) and anti-mouse (IRDye 680LT) for 1 h at room temperature before reading at 700/800 
nm on an Odyssey SA imaging system (LI-COR Biosciences). 
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2.8. Statistical Analysis 
Statistical analysis was performed using two-way ANOVA followed by Dunnett’s or Tukey’s 
multiple comparisons test with a 95% confidence level. P < 0.05 was deemed statistically significant. 
3. Results and Discussion 
3.1. BMPR2 Expression Is Decreased and TRAIL Expression Is Increased in the SuHx Model of PAH 
To determine whether we could recapitulate molecular characteristics of the SuHx model and 
whether this model was suitable to investigate the role of TRAIL in PAH vascular remodelling, we 
first looked to determine whether BMPR2 expression was decreased, and TRAIL expression increased 
within the lungs. After 3 weeks exposure to Sugen5416 plus hypoxia BMPR2 protein levels were 
significantly reduced compared to normoxic control C57Bl/6 (wt) mice (Figure 1A). On the contrary, 
TRAIL protein expression was significantly increased in whole lungs lysates from hypoxia and  
SuHx-treated wt mice, compared with normoxic or Sugen-alone treated mice (Figure 1B). TRAIL 
protein expression was also detected within remodelled pulmonary arteries of hypoxic and SuHx wt 
mice (Figure 1C). 
Figure 1. BMPR2 expression is reduced and TRAIL expression is increased in the SuHx 
mouse model. Bar graph shows (A) reduced BMPR2 expression and (B) increased TRAIL 
protein expression in whole lung protein lysates of C57Bl/6 mice following 3-week 
exposure to normoxia (Nx), Sugen-alone (Su), hypoxia-alone (Hx) and Sugen plus 
Hypoxia (SuHx). Representative western immunoblot images are also shown.  
(C) Representative photomicrographs of lung sections of SuHx mice showing 
immunoreactivity for TRAIL. Arrows highlight TRAIL positive cells within remodelled 
vessels. Error bars represent mean ± SEM, * P < 0.05, ** p < 0.01; n = 3–4 animals per 
group. Scale bars represent 50 µm. 
 
3.2. TRAIL−/−Mice Show no Echocardiographic Signs of PAH in Response to SuHx 
Compared to control normoxic, Sugen-alone and hypoxia-alone treated mice, wt mice exposed to 
SuHx displayed outward signs of morbidity including breathlessness, consistent with a PAH 
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phenotype. Serial echocardiography performed on wt mice exposed to SuHx displayed a PAH 
phenotype, as defined by a reduction in pulmonary artery acceleration time (PA-AT) (Figure 2A), 
cardiac output (Figure 2B), pulmonary artery velocity time integral (PA-VTi) (Figure 2E) and an increased 
right ventricular internal diameter at diastole (RVIDd) (Figure 2D). Hypoxia- and SuHx-treated 
TRAIL−/− mice however, displayed no significant change in either parameter compared to baseline or 
normoxic control mice. Both wt and TRAIL−/− hypoxic mice did however show a significant decrease 
in aortic-VTi (Figure 2F), presumably due to hypoxia mediated peripheral vasodilation [31].There 
were however no significant changes observed to the left ventricular wall, LV FWTs (Figure 2C) and 
LV FWTd (Figure 2G). The SuHx-treated wt mice were the only group to display a significant 
increase in RVIDd (Figure 2D). There was significant increase in RVH from both hypoxia and SuHx 
treated wt mice that was not observed in the TRAIL−/− mice. Although there was a trend for increased 
RVH between SuHx and hypoxia alone wt mice, this was not statistically significant (Figure 2H).  
Figure 2. TRAIL−/− mice show no echocardiographic signs of PAH in response to SuHx. 
(A–H) Bar graphs show (A) pulmonary artery acceleration time (PA-AT), (B) cardiac 
output, (C) left ventricle free wall thickness at systole (LV FWTs), (D) right ventricular 
internal diameter at diastole (RVIDd), (E) pulmonary artery velocity time integral (PA-VTi), 
(F) aortic velocity time integral Ao-VTi), (G) left ventricle free wall thickness at diastole 
(LV FWTd) and (H) right ventricular hypertrophy (RVH) in wt and TRAIL−/− mice at baseline 
and after 3 weeks exposure to normoxia, Sugen5416, hypoxia or SuHx. Error bars represent 
mean ± SEM, n = 4–6 animals in each group. * P < 0.05; ** P < 0.01; *** P < 0.001,  
wt mice compared to wt baseline. # P < 0.05, TRAIL−/− compared to TRAIL−/− baseline. 
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Figure 2. Cont. 
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3.3. TRAIL−/− Mice Show no Significant Haemodynamic Signs of PAH in Response to SuHx 
Following echocardiography assessment, right and left ventricular catheterisation was performed. 
Wild-type mice exposed to hypoxia and SuHx developed significant increases in RVSP (Figure 3A), 
RV dP/dtmax (Figure 3C), RV P@dP/dtmax (Figure 3E) and ePVRI (Figure 3M), and reduced cardiac 
output (Figure 3F), RV dV/dt (Figure 3D) and LV dV/dt (Figure 3K). In contrast to wt mice, hypoxia- 
and SuHx-treated TRAIL−/− mice did not develop significant changes in the haemodynamic parameters 
associated with disease development (Figure 3A–N). Wild-type SuHx-treated mice had significantly 
increased RVSP (Figure 3A) and ePVRi (Figure 3M) compared to hypoxia alone, and were the only 
group to display a significant increase in right ventricular pressure at max dP/dt (Figure 3E) suggesting 
a more severe PAH phenotype similar to that reported by Ciuclan et al. [28]. 
3.4. TRAIL−/− Mice Show Reduced Pulmonary Vascular Remodelling in Response to SuHx 
To examine whether the more severe PAH phenotype in SuHx wt mice, compared to hypoxia alone, 
was due to more extensive pulmonary vascular remodelling, and whether the TRAIL−/− mice were 
protected from pulmonary vascular changes, we performed quantitative analysis of serial lung sections. 
To assess the degree of pulmonary vascular remodelling, we measured the media cross sectional area 
(media/CSA) and degree of muscularization in pulmonary arteries of <50 µm, 50–100 µm and >100 µm 
in diameter as previously described [11,14]. Wild-type mice showed increased media/CSA (Figure 4A) 
and a greater percentage of muscularized arteries (Figure 4B) in pulmonary arterioles of <50 µm 
diameter when treated with hypoxia alone or SuHx, compared to normoxic controls. Although there 
was no significant difference between hypoxia and SuHx wt mice with either index, there were trends 
for both a higher percentage of remodelled vessels, and increased medial area. The more severe 
haemodynamics observed in the wt SuHx was likely due to the more progressive nature of the 
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pulmonary vascular remodelling as demonstrated by the significant increase in media/CSA (Figure 4D), 
and percentage remodelling (Figure 4E) of the medium sized 50-100 µm pulmonary arteries, which 
was not observed in the hypoxia alone wt mice. No difference in media/CSA, or in percentage 
muscularization was observed in pulmonary arterioles of >100 µm (Figure 4G,H). TRAIL−/− mice 
displayed no significant increases in either marker of pulmonary vascular remodelling in response to 
either hypoxia or SuHx (Figure 4A–F). To verify that the increased vascular remodelling was driven 
by pulmonary vascular cell proliferation, we performed immunohistochemical analysis of proliferating 
cell nuclear antigen (PCNA). There was little difference between wt and TRAIL−/− mice in response to 
hypoxia, perhaps highlighting that the major driver of apparent muscularisation of the pulmonary 
arteries was more vasoconstriction, rather than aberrant proliferation (Figure 4C,F,I). Within the SuHx 
wt mice however, there was a marked and significant increase in the number of proliferating cells 
within the remodelled vessels (Figure 4 C,F,I). 
Figure 3. TRAIL−/− mice show no haemodynamic signs of PAH in response to SuHx.  
(A–N) Bar graphs show (A) right ventricular systolic pressure (RVSP), (B) right ventricular 
end-diastolic pressure (RVEDP), (C) right ventricular (RV) dP/dt, (D) right ventricular 
(RV) dV/dt, (E) right ventricular (RV) P@dP/dt, (F) cardiac output, (G) mean aortic blood 
pressure (mAoP), (H) left ventricular end-systolic pressure (LVESP), (I) left ventricular 
end-diastolic pressure (LVEDP), (J) left ventricular (LV) dP/dt, (K) left ventricular (LV) 
dV/dt, (L) left ventricular (LV) P@dP/dt, (M) estimated pulmonary vascular resistance 
(ePVRi) and (N) systemic vascular resistance (SVR) in wt and TRAIL−/− mice after  
3 weeks exposure to normoxia, Sugen5416, hypoxia or SuHx. Error bars represent  
mean ± SEM, n = 3–6 animals in each group. * P < 0.05; ** P < 0.01; **** P < 0.0001, 
compared to wt normoxic mice, significant differences between other groups are shown. 
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Figure 3. Cont. 
 
Histological and immunohistological analysis of lung tissues (Figure 5) revealed evidence of 
muscularization caused by increased smooth muscle actin (SMA) positive cells in small resistance 
pulmonary arterioles, <50 µm diameter, in hypoxic and SuHx mice compared to normoxic mice. 
Although more extensive pulmonary vascular remodelling was observed in the SuHx treated wt mice 
we did not observe any evidence of plexiform-like lesions. TRAIL−/− mice displayed reduced 
remodelling of the pulmonary arterioles in response to both hypoxia and SuHx that corresponded with 
the presence or absence of proliferating cells (PCNA, Figure 5). 
3.5. The Protection from Pulmonary Vascular Remodelling in TRAIL−/− Mice in the SuHx Model Is 
Associated with Reduced Recruitment of Inflammatory Cells 
Previous studies in chimeric mice suggest that tissue expression of TRAIL is the predominant 
driver of pulmonary remodelling in the high fat diet fed ApoE−/− mouse model [14], however the 
contribution of bone marrow (BM)-derived cells could not be entirely ruled out. To determine whether 
protection from the development of a PAH phenotype was also associated with a reduced 
inflammatory cell infiltration, we performed immunohistochemical analysis for CD45 positive cells in 
SuHx wt and TRAIL−/− mice. While wt mice demonstrated a marked increase in CD45 positive cells in 
response to SuHx, TRAIL−/− mice had a similar expression profile to control wt mice (Figure 6).  
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Figure 4. TRAIL−/− mice show reduced pulmonary vascular muscularization in response to 
SuHx. Bar graphs show media/CSA of pulmonary arteries (A) <50 µm diameter,  
(D) 50–100 µm diameter, (G) >100 µm diameter; the percentage of muscularized arteries 
(B) <50 µm diameter, (E) 50–100 µm diameter, (H) >100 µm diameter; percentage of 
proliferating cells within pulmonary arteries (C) <50 µm diameter, (F) 50–100 µm 
diameter, (I) >100 µm diameter in wt and TRAIL−/− mice exposed to normoxia (Nx), 
sugen-alone (Su), hypoxia (Hx) and Sugen plus Hypoxia (SuHx). Error bars represent 
mean ± SEM, n = 3–6 animals in each group. * P < 0.05; ** P < 0.01; *** P < 0.001, 
compared to wt normoxic mice.  
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Figure 5. TRAIL−/− mice are protected against small resistance pulmonary arterial 
muscularization when exposed to SuHx. Representative photomicrographs of lung sections 
from wt and TRAIL−/− mice after 3-week exposure to normoxia, Sugen 5416, hypoxia or 
SuHx. Sections were stained with Alcian Blue Elastic van Gieson (ABEVG), 
immunostained for α-smooth muscle actin (SMA) or proliferating smooth muscle cell 
antigen (PCNA). Bars, 50 µm. 
 
Figure 6. TRAIL−/− recruit less CD45 positive cells when exposed to SuHx. 
Representative photomicrographs of lung sections from wt and TRAIL−/− mice after  
3-week exposure to Sugen plus hypoxia (SuHx). Sections were immunostained for CD45.  
 
4. Conclusions  
Rodent models, and particularly murine models of PAH, are often criticised for their limited ability 
to recapitulate or model human disease. Despite these caveats, the increasing availability of knockout 
and transgenic mice increases the importance of mouse models. The hypoxic mouse model has historically 
been the most common murine model [25] utilised despite the mouse being a poor responder to 
hypoxia, in comparison to other species, and therefore a weak model [26]. The recent adaptation of the 
rat Sugen-hypoxic (SuHx) [27] to mice by Ciuclan and colleagues [28] provides a more robust murine 
model in which to test the requirement, or importance of specific genes in disease pathogenesis. 
We have previously demonstrated that TRAIL−/− mice are protected from hypoxia-induced PH, and 
that ApoE−/−/TRAIL−/− are protected from high fat diet-induced PAH [14]. We therefore looked to test 
the utility of the murine SuHx model while simultaneously validating our own studies. We found that 
while C57BL/6 mice developed hallmarks of PAH as measured by echocardiography, cardiac 
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catheterisation and remodelling of the small pulmonary arterioles as previously reported [28], 
TRAIL−/− mice showed no significant signs of PAH, as evidenced by the reduced recruitment of 
inflammatory cells and reduced number of proliferating cells with the pulmonary arteries. These data 
emphasise the utility of the murine SuHx models as a tool to screen the importance of particular genes 
of interest, and further support the importance of TRAIL in the pathogenesis of PAH. 
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